Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (24815)	8/20/1998 1:15:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

Sounds like the poodle couldn't come up with any examples of buy recs with lowering of earnings estimates. Typical poodle post with no facts to back up his accusations, only name calling. Also if biotechs are valued on future rather than present earnings, why did Lgnd lose half its value? Best pipeline in the industry should support future earnings. From 18 to 8 must be a problem. <Luckily biotech analysts know better> Besides the knowledgable people on this thread, what analyst predicted the 18 to 8 fall in Lgnd's price. All I have seen is buy recs from analyst. Guess they don't want to admit they had buys out when it was 18.